DE69232615T2 - Zusammensetzungen zur verhütung und/oder behandlung von pathologischen prozessen - Google Patents

Zusammensetzungen zur verhütung und/oder behandlung von pathologischen prozessen

Info

Publication number
DE69232615T2
DE69232615T2 DE69232615T DE69232615T DE69232615T2 DE 69232615 T2 DE69232615 T2 DE 69232615T2 DE 69232615 T DE69232615 T DE 69232615T DE 69232615 T DE69232615 T DE 69232615T DE 69232615 T2 DE69232615 T2 DE 69232615T2
Authority
DE
Germany
Prior art keywords
lmwh
present
pathological processes
compositions
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69232615T
Other languages
English (en)
Other versions
DE69232615D1 (de
Inventor
Irun R Cohen
Ofer Lider
Rami Herskovitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL9802891A external-priority patent/IL98028A/en
Priority claimed from IL98298A external-priority patent/IL98298A0/xx
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of DE69232615D1 publication Critical patent/DE69232615D1/de
Application granted granted Critical
Publication of DE69232615T2 publication Critical patent/DE69232615T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE69232615T 1991-05-02 1992-05-01 Zusammensetzungen zur verhütung und/oder behandlung von pathologischen prozessen Expired - Lifetime DE69232615T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL9802891A IL98028A (en) 1991-05-02 1991-05-02 Pharmaceuticals containing low molecular weight heparin (HWML)
IL98298A IL98298A0 (en) 1991-05-28 1991-05-28 Pharmaceutical compositions comprising a heparin derivative
PCT/US1992/003626 WO1992019249A1 (en) 1991-05-02 1992-05-01 Compositions for the prevention and/or treatment of pathological processes

Publications (2)

Publication Number Publication Date
DE69232615D1 DE69232615D1 (de) 2002-06-27
DE69232615T2 true DE69232615T2 (de) 2003-01-30

Family

ID=26322260

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69232615T Expired - Lifetime DE69232615T2 (de) 1991-05-02 1992-05-01 Zusammensetzungen zur verhütung und/oder behandlung von pathologischen prozessen

Country Status (15)

Country Link
US (3) US5474987A (de)
EP (1) EP0583360B1 (de)
JP (1) JPH06507635A (de)
KR (1) KR100235782B1 (de)
AT (1) ATE217796T1 (de)
AU (1) AU668865B2 (de)
BR (1) BR9205961A (de)
CA (1) CA2102207A1 (de)
CZ (1) CZ232593A3 (de)
DE (1) DE69232615T2 (de)
FI (1) FI934849A (de)
HU (1) HUT67136A (de)
NO (1) NO933942L (de)
SK (1) SK120193A3 (de)
WO (1) WO1992019249A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US6750207B1 (en) * 1992-05-01 2004-06-15 Yeda Research And Development Co. Ltd. Compositions for the regulation of cytokine activity
CA2149116A1 (en) * 1992-11-10 1994-05-26 Irun R. Cohen Compositions for the regulation of cytokine activity
WO1994018988A2 (en) * 1993-02-22 1994-09-01 Von Arnim Ulrich Christoph Use of heparins for the treatment of inflammatory or immunological diseases
US5980865A (en) * 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
US6217863B1 (en) 1995-10-30 2001-04-17 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase I
SI0946185T2 (sl) * 1996-11-27 2010-08-31 Aventis Pharma Inc Farmacevtski sestavek, ki obsega spojino z anti-Xa-aktivnostjo in antagonistično spojino za agregacijo ploščic
CN1287852C (zh) 1997-07-14 2006-12-06 村松乔 含有midkine或其抑制剂作为活性成分的药剂
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
EP1109919A2 (de) 1998-08-27 2001-06-27 Massachusetts Institute Of Technology Von heparinase i und ii abgeleitete heparinasen
IL127851A0 (en) 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
CA2370539C (en) 1999-04-23 2009-01-06 Massachusetts Institute Of Technology System and method for notating polymers
EP1192187A1 (de) * 1999-06-30 2002-04-03 Hamilton Civic Hospitals Research Development, Inc. Heparinzusammensetzungen, die gerinnselzugehörige gerinnungsfakoren verhindert
CA2402160C (en) * 2000-03-08 2012-02-14 Massachusetts Institute Of Technology Heparinase iii and uses thereof
HUP0300939A2 (hu) * 2000-09-08 2003-09-29 Hamilton Civic Hospitals Research Development, Inc. Antitrombotikus készítmények
AU2001292618A1 (en) 2000-09-12 2002-03-26 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
AU2440802A (en) 2000-10-18 2002-04-29 Massachusetts Inst Technology Methods and products related to pulmonary delivery of polysaccharides
ES2238383T3 (es) * 2000-12-16 2005-09-01 Aventis Pharma Deutschland Gmbh Uso de heparina de bajo peso molecular para el tratamiento de la osteoartrosis.
CA2451245A1 (en) * 2001-06-25 2003-01-03 Depuy International Limited Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints
WO2003011119A2 (en) * 2001-07-31 2003-02-13 Reddy Us Therapeutics, Inc. Methods and compositions for diagnosis and treatment of vascular conditions
US20040241689A1 (en) * 2001-07-31 2004-12-02 Baseman Joel B. Antigens of and antibodies to translocated molecules of microorganisms and uses thereof
US7285536B2 (en) * 2001-12-05 2007-10-23 Yeda Research And Development Co., Ltd. Anti-cancer therapeutic compounds
WO2003088980A1 (en) * 2002-04-18 2003-10-30 Embury Stephen H Method and composition for preventing pain in sickle cell patients
US8071569B2 (en) * 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
AU2004208038B2 (en) 2003-01-30 2007-09-06 Prochon Biotech Ltd. Freeze-dried fibrin matrices and methods for preparation thereof
WO2005054493A2 (en) * 2003-06-12 2005-06-16 Mayo Foundation For Medical Education And Research Altered activity of toll-like receptors
EP1641913B1 (de) 2003-06-27 2016-01-06 DePuy Synthes Products, Inc. Aus der nabelschnur abgeleitete postpartum zellen und deren herstellungsmethoden und verwendung
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
EP1667633A4 (de) * 2003-10-01 2008-10-08 Momenta Pharmaceuticals Inc Polysaccharide zur pulmonalen abgabe von wirkstoffen
CA2534445A1 (en) * 2004-03-29 2005-10-06 Kringle Pharma Inc. Agent for promoting hgf production comprising heparin-like oligosaccharides
US8450297B2 (en) * 2004-08-16 2013-05-28 Massachusetts Institute Of Technology Rapid two-step synthesis of anti-coagulants
PL1831356T3 (pl) 2004-12-23 2017-07-31 DePuy Synthes Products, Inc. Komórki poporodowe pochodzące z tkanki pępowinowej i sposoby ich wytwarzania i stosowania
EP1906974A4 (de) * 2005-07-22 2010-06-23 Univ California Heparinzusammensetzungen und selectin-hemmung
WO2007035778A2 (en) 2005-09-19 2007-03-29 Histogenics Corporation Cell-support matrix and a method for preparation thereof
AU2009250803A1 (en) * 2008-05-20 2009-11-26 Crystal Clear Partnership Separation of polysaccharides by charge density gradient
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61201A (en) * 1979-10-05 1984-09-30 Choay Sa Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them
US4281108A (en) * 1980-01-28 1981-07-28 Hepar Industries, Inc. Process for obtaining low molecular weight heparins endowed with elevated pharmacological properties, and product so obtained
CA1226816A (en) * 1982-12-20 1987-09-15 Moses J. Folkman Inhibition of angiogenesis
US4916219A (en) * 1985-03-28 1990-04-10 University Of Iowa Research Foundation Oligosaccharide heparin fragments as inhibitors of complement cascade
IT1214609B (it) * 1985-05-17 1990-01-18 Opocrin Spa Esosaminoglicani solfati depolimerizzati ad attivita'antitrombotica, fibrinolitica, antinfiammatoria, loro procedimento di preparazione e composizioni farmaceutiche che li contengono.
US4889808A (en) * 1985-10-01 1989-12-26 American Home Products Method of enchancing t-PA and SCU-PA production
EP0240098A3 (de) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo und Polysaccharide zur Behandlung von Krankheiten verursacht durch Retroviren
US4788307A (en) * 1986-04-30 1988-11-29 Choay S.A. Oligosaccharidic fractions devoid or practically devoid of antithrombotic activity
DE3787996T2 (de) * 1986-05-16 1994-03-03 Italfarmaco Spa Heparine, frei von E.D.T.A., Fraktionen und Fragmente von Heparin, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, welche diese enthalten.
WO1988000017A1 (en) * 1986-06-27 1988-01-14 Boon Corporation Pty. Ltd. Mat
IL85145A (en) * 1987-01-23 1994-08-26 Univ Australian Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
SE8702254D0 (sv) * 1987-05-29 1987-05-29 Kabivitrum Ab Novel heparin derivatives
AU4426289A (en) * 1988-10-05 1990-05-01 Nicola Diferrante Methods for interfering with hiv multiplication and composition for the treatment of aids
IL88554A0 (en) * 1988-12-01 1989-07-31 Hadassah Med Org Compositions containing a compound binding to a heparin receptor
PT93847A (pt) * 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
AT500533B8 (de) * 2000-04-13 2007-02-15 Man Nutzfahrzeuge Ag Gas- oder trolleybus

Also Published As

Publication number Publication date
US5474987A (en) 1995-12-12
BR9205961A (pt) 1994-07-26
DE69232615D1 (de) 2002-06-27
EP0583360A1 (de) 1994-02-23
ATE217796T1 (de) 2002-06-15
EP0583360A4 (de) 1994-04-06
NO933942L (no) 1993-12-14
CZ232593A3 (en) 1994-07-13
AU1913192A (en) 1992-12-21
EP0583360B1 (de) 2002-05-22
SK120193A3 (en) 1994-07-06
JPH06507635A (ja) 1994-09-01
FI934849A0 (fi) 1993-11-02
US5908837A (en) 1999-06-01
CA2102207A1 (en) 1992-11-03
WO1992019249A1 (en) 1992-11-12
HUT67136A (en) 1995-02-28
KR100235782B1 (ko) 1999-12-15
HU9303110D0 (en) 1994-01-28
FI934849A (fi) 1993-12-31
US5686431A (en) 1997-11-11
AU668865B2 (en) 1996-05-23
NO933942D0 (no) 1993-11-01

Similar Documents

Publication Publication Date Title
DE69232615T2 (de) Zusammensetzungen zur verhütung und/oder behandlung von pathologischen prozessen
NZ263736A (en) An inhibitor of stem cell proliferation for treating hyperproliferative conditions
ATE232102T1 (de) Behandlung von arthrose, rheumatoider arthrose und erscheinungen verwandt an arthrose
DK0781278T3 (da) Nye benzothiepiner, som har aktivitet som inhibitorer af ileal galdsyretransport og taurocholatoptagelse
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
MD1507G2 (ro) Inhibitori, compoziţie farmaceutică pe baza lor şi procedeu de inhibare a HIV proteazei
ATE218164T1 (de) Hemmung der fortpflanzung von arterienglattmuskelzellen
EP0675899A4 (de) NEUE INHIBITOREN VON FAKTOR Xa.
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
PL316197A1 (en) Benzothiophene, benzofuran and indole thiazepinones, oxazepinones and diazepinones as agents preventing adhesion of cells and inhibiting activity of hiv virus
DE69033970T2 (de) Huperzin a analoge verbindungen
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
EE04044B1 (et) Farmatseutilised tooted veresoonte endoteelirakkude kahjustuste tagajärjel tekkinud haiguste raviksja vältimiseks
NO943126D0 (no) 3-alkyloksy-, aryloksy- eller arylalkyloksybenzo-[bÅtiofen-2-karboksamider som hemmere av celleadhesjon
DE69819922D1 (de) 2-Amino-6-methyl-7-acetyl-tetralin und pharmazeutische Zusammensetzungen zur Vorbeugung und therapeutischen Behandlung von entzündlichen und/oder Autoimmunkrankheiten
DE69433110D1 (de) Allogenes vakzin und synthesemethode für selbiges
RU93058322A (ru) Композиции для предотвращения и/или лечения патологических процессов, способ применения низкомолекулярного гепарина, способ лечения
SE8306792D0 (sv) Neues terapeutisches preparat enthaltend hydrierte ergotalkaloide und heparin
Gallily et al. Mouse macrophage functions under the influence of factors released by spleen cells preincubated with the methanol extraction residue (MER) tubercle bacillus fraction
DE69109933T2 (de) Verwendung von Mizoribin zur Behandlung oder Vorbeugung der Multiplen Sklerose.
RU97117918A (ru) Способ адаптивной иммунотерапии злокачественных новообразований
ATE280584T1 (de) Verwendung von beta interferon zur herstellung eines arzneimittels zur behandlung von ewings sarkom und eoe

Legal Events

Date Code Title Description
8364 No opposition during term of opposition